Pfizer (PFE), Pain Therapeutics (PTIE) Receive Complete Response Letter from FDA for Pain Relief Candidate

QualityStocks would like to highlight Pain Therapeutics, Inc. (NASDAQ: PTIE), a biopharmaceutical company that develops novel drugs. In addition to REMOXY, a unique, abuse-resistant controlled-release oxycodone, the company has three drug candidates in clinical programs, including a novel radio-labeled monoclonal antibody to treat metastatic melanoma, as well as PTI-202 and PTI-721. Pain Therapeutics is also working on a new treatment for patients with hemophilia.

In the company’s news Friday,

Pfizer Inc. and Pain Therapeutics announced they received word from the U.S. Food and Drug Administration (FDA) regarding the resubmission of a new drug application (NDA) for REMOXY® (oxycodone) Extended-Release Capsules CII.

REMOXY is an investigational extended-release oral formulation of oxycodone for the relief of moderate to severe pain.

In 2005, Pain Therapeutics signed an agreement with King Pharmaceuticals Inc. to develop and commercialize REMOXY. In 2008, Pain Therapeutics filed the initial NDA for REMOXY. The following year, King Pharmaceuticals assumed full control of drug development and filed a resubmission to the initial NDA in 2010.

Earlier this year, Pfizer acquired King Pharmaceuticals, thereby obtaining rights to REMOXY. The company is now working to respond and coordinate additional talks with the FDA.

“Pfizer is working to understand and address the issues in the FDA Complete Response Letter,” Olivier Brandicourt, Pfizer president and general manager of Primary Care stated in the press release. “Pain is an important strategic disease area for Pfizer. We share the concern about misuse and abuse of opioid medicines and are committed to being part of the solution to address this important public health and safety issue.”

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.